Back to top

Daiwa Reaffirms Their Buy Rating on BeOne Medicines Ltd (6160)

In a report released on August 12, from Daiwa maintained a Buy rating on BeOne Medicines Ltd, with a price target of HK$270.00. The company’s share...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

BeOne Medicines Ltd. - Sponsored ADR (ONC)